Protocol Ledger

NCT06492837 · Phase II · ACTIVE NOT RECRUITING

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Interventional Phase II clinical trial protocol NCT06492837 sponsored by Fondazione Italiana Linfomi - ETS in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-23 Enrollment: 56 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06492837
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)56 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06492837
Protocol FieldVerified Registry Value
NCT IdentifierNCT06492837
Consolidated Lead SponsorFondazione Italiana Linfomi - ETS
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment56 participants (ESTIMATED)
Registered Start Date2024-10-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06492837
Hospital Research SiteLocationSite Profile
Royal Adelaide HospitalAdelaide, AustraliaOpen Hospital Dossier ->
Liverpool HospitalLiverpool, AustraliaOpen Hospital Dossier ->
Princess Alexandra HospitalWoolloongabba, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI